Regulus Historical Income Statement

RGLS Stock

USD 1.61 0.03 1.83%

Historical analysis of Regulus Therapeutics income statement accounts such as Research Development of 24.1 M, Cost Of Revenue of 22.8 M, Total Operating Expenses of 9.5 M or Total Other Income Expense Net of 1.1 M can show how well Regulus Therapeutics performed in making a profits. Evaluating Regulus Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Regulus Therapeutics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Regulus Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Regulus Therapeutics is a good buy for the upcoming year.

Net Income Gross Profit

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regulus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Regulus Stock please use our How to Invest in Regulus Therapeutics guide.

About Regulus Income Statement Analysis

Regulus Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Regulus Therapeutics shareholders. The income statement also shows Regulus investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Regulus Therapeutics Income Statement Chart

At this time, Regulus Therapeutics' Interest Income is comparatively stable compared to the past year. Net Interest Income is likely to gain to about 1 M in 2024, whereas Total Revenue is likely to drop 0.00 in 2024.

Depreciation And Amortization Other Operating Expenses Research Development Cost Of Revenue Total Operating Expenses

Depreciation And Amortization

The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Regulus Therapeutics. It is also known as Regulus Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Cost Of Revenue

Cost of Revenue is found on Regulus Therapeutics income statement and represents the costs associated with goods and services Regulus Therapeutics provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from Regulus Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Regulus Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regulus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Regulus Stock please use our How to Invest in Regulus Therapeutics guide.At this time, Regulus Therapeutics' Interest Income is comparatively stable compared to the past year. Net Interest Income is likely to gain to about 1 M in 2024, whereas Total Revenue is likely to drop 0.00 in 2024.

	2021	2022	2023	2024 (projected)
Interest Expense	855K	688K	604K	1.1M
Depreciation And Amortization	459K	122K	227K	215.7K

Interest Expense Depreciation And Amortization

Regulus Therapeutics income statement Correlations

	Depreciation And Amortization	Interest Expense	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Selling General Administrative	Net Income From Continuing Ops	Non Operating Income Net Other	Tax Provision	Interest Income	Net Interest Income	Reconciled Depreciation	Extraordinary Items	Selling And Marketing Expenses
Depreciation And Amortization		0.37	0.05	0.3	0.79	-0.72	-0.72	0.8	-0.7	0.82	0.85	-0.75	-0.31	-0.75	0.02	0.65	-0.78	-0.07	-0.36	-0.31	-0.57	0.73	-0.42	0.42
Interest Expense	0.37		-0.54	-0.29	0.14	-0.31	-0.35	0.07	-0.34	-0.04	0.14	-0.28	0.16	-0.28	-0.4	0.37	-0.27	0.47	-0.27	-0.34	-0.71	-0.18	-0.09	0.03
Total Revenue	0.05	-0.54		0.83	-0.02	0.35	0.35	0.03	0.37	0.17	0.11	0.32	-0.17	0.32	0.01	-0.19	0.29	-0.24	0.02	-0.26	-0.05	0.51	-0.35	0.35
Gross Profit	0.3	-0.29	0.83		0.09	0.2	0.2	0.13	0.22	0.18	0.35	0.15	-0.31	0.15	-0.05	-0.06	0.11	-0.25	-0.07	-0.68	-0.43	0.64	-0.79	0.77
Other Operating Expenses	0.79	0.14	-0.02	0.09		-0.94	-0.93	0.99	-0.93	0.89	0.94	-0.94	-0.17	-0.94	-0.05	0.9	-0.95	-0.06	-0.35	0.01	-0.17	0.48	-0.16	0.15
Operating Income	-0.72	-0.31	0.35	0.2	-0.94		0.99	-0.92	0.99	-0.77	-0.85	0.99	0.1	0.99	0.05	-0.91	0.98	-0.03	0.34	-0.09	0.14	-0.28	0.03	-0.02
Ebit	-0.72	-0.35	0.35	0.2	-0.93	0.99		-0.91	1.0	-0.75	-0.84	0.97	-0.01	0.97	0.06	-0.91	0.96	-0.15	0.34	-0.09	0.15	-0.26	0.02	-0.01
Research Development	0.8	0.07	0.03	0.13	0.99	-0.92	-0.91		-0.9	0.93	0.94	-0.92	-0.2	-0.92	-0.01	0.84	-0.93	-0.11	-0.37	0.04	-0.13	0.56	-0.18	0.15
Ebitda	-0.7	-0.34	0.37	0.22	-0.93	0.99	1.0	-0.9		-0.74	-0.83	0.96	-0.02	0.96	0.06	-0.91	0.96	-0.15	0.33	-0.11	0.13	-0.24	0.01	0.0
Cost Of Revenue	0.82	-0.04	0.17	0.18	0.89	-0.77	-0.75	0.93	-0.74		0.83	-0.8	-0.33	-0.8	0.14	0.66	-0.82	-0.28	-0.36	0.12	-0.1	0.73	-0.12	0.11
Total Operating Expenses	0.85	0.14	0.11	0.35	0.94	-0.85	-0.84	0.94	-0.83	0.83		-0.86	-0.27	-0.86	-0.08	0.83	-0.88	-0.11	-0.36	-0.29	-0.37	0.61	-0.46	0.45
Income Before Tax	-0.75	-0.28	0.32	0.15	-0.94	0.99	0.97	-0.92	0.96	-0.8	-0.86		0.24	1.0	0.06	-0.89	0.99	0.1	0.34	-0.05	0.17	-0.33	0.08	-0.07
Total Other Income Expense Net	-0.31	0.16	-0.17	-0.31	-0.17	0.1	-0.01	-0.2	-0.02	-0.33	-0.27	0.24		0.24	0.05	-0.04	0.24	0.88	0.09	0.27	0.23	-0.4	0.33	-0.33
Net Income	-0.75	-0.28	0.32	0.15	-0.94	0.99	0.97	-0.92	0.96	-0.8	-0.86	1.0	0.24		0.05	-0.89	0.99	0.1	0.34	-0.05	0.17	-0.33	0.08	-0.07
Income Tax Expense	0.02	-0.4	0.01	-0.05	-0.05	0.05	0.06	-0.01	0.06	0.14	-0.08	0.06	0.05	0.05		-0.14	0.01	-0.15	0.33	0.33	0.39	0.24	0.09	-0.09
Selling General Administrative	0.65	0.37	-0.19	-0.06	0.9	-0.91	-0.91	0.84	-0.91	0.66	0.83	-0.89	-0.04	-0.89	-0.14		-0.88	0.12	-0.27	-0.06	-0.26	0.15	-0.08	0.09
Net Income From Continuing Ops	-0.78	-0.27	0.29	0.11	-0.95	0.98	0.96	-0.93	0.96	-0.82	-0.88	0.99	0.24	0.99	0.01	-0.88		0.11	0.36	-0.03	0.18	-0.39	0.11	-0.1
Non Operating Income Net Other	-0.07	0.47	-0.24	-0.25	-0.06	-0.03	-0.15	-0.11	-0.15	-0.28	-0.11	0.1	0.88	0.1	-0.15	0.12	0.11		-0.02	0.02	-0.11	-0.35	0.16	-0.16
Tax Provision	-0.36	-0.27	0.02	-0.07	-0.35	0.34	0.34	-0.37	0.33	-0.36	-0.36	0.34	0.09	0.34	0.33	-0.27	0.36	-0.02		0.0	0.28	-0.28	0.13	-0.13
Interest Income	-0.31	-0.34	-0.26	-0.68	0.01	-0.09	-0.09	0.04	-0.11	0.12	-0.29	-0.05	0.27	-0.05	0.33	-0.06	-0.03	0.02	0.0		0.83	-0.27	0.83	-0.84
Net Interest Income	-0.57	-0.71	-0.05	-0.43	-0.17	0.14	0.15	-0.13	0.13	-0.1	-0.37	0.17	0.23	0.17	0.39	-0.26	0.18	-0.11	0.28	0.83		-0.33	0.63	-0.63
Reconciled Depreciation	0.73	-0.18	0.51	0.64	0.48	-0.28	-0.26	0.56	-0.24	0.73	0.61	-0.33	-0.4	-0.33	0.24	0.15	-0.39	-0.35	-0.28	-0.27	-0.33		-0.53	0.52
Extraordinary Items	-0.42	-0.09	-0.35	-0.79	-0.16	0.03	0.02	-0.18	0.01	-0.12	-0.46	0.08	0.33	0.08	0.09	-0.08	0.11	0.16	0.13	0.83	0.63	-0.53		-0.8
Selling And Marketing Expenses	0.42	0.03	0.35	0.77	0.15	-0.02	-0.01	0.15	0.0	0.11	0.45	-0.07	-0.33	-0.07	-0.09	0.09	-0.1	-0.16	-0.13	-0.84	-0.63	0.52	-0.8

Click cells to compare fundamentals

Regulus Therapeutics Account Relationship Matchups

Regulus Therapeutics income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	931K	467K	459K	122K	227K	215.7K
Interest Expense	2.1M	1.8M	855K	688K	604K	1.1M
Gross Profit	6.8M	10.0M	(459K)	(122K)	(21.2M)	(20.1M)
Other Operating Expenses	23.7M	24.2M	27.8M	28.2M	31.1M	32.6M
Operating Income	(16.8M)	(14.2M)	(27.8M)	(28.2M)	(31.1M)	(32.7M)
Ebit	(16.8M)	(14.2M)	(27.8M)	(28.2M)	(31.1M)	(32.7M)
Research Development	12.3M	15.3M	17.8M	18.4M	21.2M	24.1M
Ebitda	(15.9M)	(13.7M)	(27.4M)	(28.1M)	(30.9M)	(32.4M)
Cost Of Revenue	12.3M	15.3K	459K	122K	21.2M	22.8M
Total Operating Expenses	23.7M	24.2M	27.8M	28.2M	10.0M	9.5M
Income Before Tax	(18.6M)	(15.7M)	(27.8M)	(28.3M)	(30.0M)	(31.5M)
Total Other Income Expense Net	(1.8M)	(1.6M)	9K	(83K)	1.1M	1.1M
Net Income	(18.6M)	(15.3M)	(27.8M)	(28.3M)	(30.0M)	(31.5M)
Selling General Administrative	11.3M	8.8M	10.0M	9.8M	10.0M	9.4M
Net Income From Continuing Ops	(18.6M)	(15.7M)	(27.8M)	(28.3M)	(28.8M)	(30.2M)
Non Operating Income Net Other	752K	459K	374K	233K	268.0K	281.3K
Net Income Applicable To Common Shares	(18.6M)	(15.7M)	(27.8M)	(28.3M)	(32.6M)	(34.2M)
Tax Provision	(197K)	62K	1K	(7K)	1.2K	1.2K
Interest Income	374K	233K	864K	605K	1.7M	1.7M
Net Interest Income	(1.8M)	(1.6M)	9K	(83K)	971K	1.0M
Reconciled Depreciation	931K	467K	459K	122K	184K	174.8K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Regulus Stock Analysis

When running Regulus Therapeutics' price analysis, check to measure Regulus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regulus Therapeutics is operating at the current time. Most of Regulus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Regulus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regulus Therapeutics' price. Additionally, you may evaluate how the addition of Regulus Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Regulus Historical Income Statement

About Regulus Income Statement Analysis

Regulus Therapeutics Income Statement Chart

Depreciation And Amortization

Other Operating Expenses

Cost Of Revenue

Total Operating Expenses

Regulus Therapeutics income statement Correlations

Regulus Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Regulus Therapeutics income statement Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Regulus Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ebitda	+ 1.0	Ebit
Net Income	+ 1.0	Income Before Tax
Research Development	+ 0.99	Other Operating Expenses
Ebit	+ 0.99	Operating Income
Ebitda	+ 0.99	Operating Income
Income Before Tax	+ 0.99	Operating Income

Net Income From Continuing Ops	- 0.95	Other Operating Expenses
Net Income	- 0.94	Other Operating Expenses
Income Before Tax	- 0.94	Other Operating Expenses
Operating Income	- 0.94	Other Operating Expenses
Net Income From Continuing Ops	- 0.93	Research Development
Ebitda	- 0.93	Other Operating Expenses